Showing 85–96 of 226 results
Mast cells are principal players in IgE-, and more recently, non-IgE-mediated anaphylactoid reactions or pseudo-allergic Adverse Drug Reactions (ADR). A…
Read MoreThe recent appreciation of functional selectivity/ligand bias in GPCR signaling has uncovered new opportunities for therapeutic discovery and continues to…
Read MoreDiscoveRx® has pioneered a novel enzyme complementation system to monitor cellular events such as protein translocation, protein interactions, and degradation…
Read MoreDiscoveRx® has pioneered a novel enzyme complementation system to monitor cellular events such as protein translocation, protein interactions, and degradation…
Read MoreDiscoveRx has developed a novel application of our established Enzyme Fragment Complementation (EFC) technology that allows us to monitor protein-protein…
Read MoreRegulatory authorities define biosimilars as drugs that are “highly similar” to or “interchangeable” with an approved biologic. The lack of…
Read MoreChimeric antigen receptor (CAR)-T cells, which are engineered to recognize target cell surface antigens expressed on tumor cells, have shown…
Read MoreGPCR activation results in G-protein dependent events such as second messenger signaling, as well as initiation of a host of…
Read MoreLigand-induced receptor dimerization is the first functional step in receptor activation, representing the most proximal, functional read-out for receptor activation.…
Read MoreAn assay platform that robustly and sensitively quantifies the kinetics of endogenous protein turnover is crucial for discovery of disease-relevant…
Read MoreOne of the major bottlenecks in the development of biosimilars is the need for good bioassays to create potency, stability…
Read MoreDiscoveRx has developed a panel of over 30 naturally Gq-coupled or dual coupled GPCR/Arrestin cell lines that can be used…
Read More
